S. Garnier

发表

Genomic characterization of metastatic breast cancers

Yahia Adnani, Thomas Bachelot, Florence Dalenc, 2019, Nature.

A Comparison of DNA Mutation and Copy Number Profiles of Primary Breast Cancers and Paired Brain Metastases for Identifying Clinically Relevant Genetic Alterations in Brain Metastases

F. Bertucci, D. Birnbaum, P. Finetti, 2019, Cancers.

A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study

D. Birnbaum, N. Vey, A. Restouin, 2020, Blood Cancer Journal.

Circulating tumor DNA predicts efficacy of a dual AKT/p70S6K inhibitor (LY2780301) plus paclitaxel in metastatic breast cancer: plasma analysis of the TAKTIC phase IB/II study

F. Bertucci, F. Dalenc, C. Vicier, 2022, Molecular oncology.

Fine analysis of atypical circulating tumor cells in metastatic breast cancer patients reveals subsets with different prognostic values

F. Bertucci, P. Finetti, C. Acquaviva, 2020, medRxiv.

Sensitive and easy screening for circulating tumor cells by flow cytometry.

F. Bertucci, D. Birnbaum, P. Finetti, 2019, JCI insight.

NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non‐inflammatory breast cancers

F. Bertucci, D. Birnbaum, P. Finetti, 2019, Molecular oncology.

Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial

F. Bertucci, D. Birnbaum, P. Finetti, 2022, Cancers.

TAKTIC: A prospective, multicentre, uncontrolled, phase IB/II study of LY2780301, a p70S6K/AKT inhibitor, in combination with weekly paclitaxel in HER2-negative advanced breast cancer patients.

F. Bertucci, D. Birnbaum, F. Dalenc, 2021, European journal of cancer.

Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia

D. Birnbaum, C. Arnoulet, N. Vey, 2015, Blood Cancer Journal.

Identification of Atypical Circulating Tumor Cells with Prognostic Value in Metastatic Breast Cancer Patients

F. Bertucci, D. Birnbaum, P. Finetti, 2022, Cancers.

Poly (ADP-Ribose) Polymerase Inhibitors for De Novo BRCA2-Null Small-Cell Prostate Cancer.

F. Bertucci, D. Birnbaum, G. Pignot, 2018, JCO precision oncology.

Targeted molecular characterization shows differences between primary and secondary myelofibrosis

D. Birnbaum, V. Ugo, F. Delhommeau, 2020, Genes, chromosomes & cancer.

Mutation patterns in essential thrombocythemia, polycythemia vera and secondary myelofibrosis

D. Birnbaum, J. Rey, N. Vey, 2019, Leukemia & lymphoma.

Genomic analysis of myeloproliferative neoplasms in chronic and acute phases

D. Birnbaum, N. Cervera, J. Rey, 2017, Haematologica.

Cyclin A2 maintains colon homeostasis and is a prognostic factor in colorectal cancer

F. Bertucci, P. Finetti, C. Paul, 2021 .

Whole-genome/exome analysis of circulating tumor DNA and comparison to tumor genomics from patients with heavily pre-treated ovarian cancer: subset analysis of the PERMED-01 trial

F. Bertucci, D. Birnbaum, A. Gonçalves, 2022, Frontiers in Oncology.

Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial

F. Bertucci, D. Birnbaum, P. Finetti, 2021, Genome Medicine.

Major Response to Carboplatin in a Patient With Metastatic Triple-Negative Breast Cancer With Somatic Mutation of BRCA1 and Loss of RAD51B.

F. Bertucci, D. Birnbaum, A. Gonçalves, 2019, JCO precision oncology.

Genomic characterization of metastatic breast cancers

F. Bertucci, D. Birnbaum, F. André, 2019, Nature.

High Response to Cetuximab in a Patient With EGFR-Amplified Heavily Pretreated Metastatic Triple-Negative Breast Cancer.

F. Bertucci, D. Birnbaum, P. Viens, 2019, JCO precision oncology.

CDKN2A/B Deletion and Double-hit Mutations of the MAPK Pathway Underlie the Aggressive Behavior of Langerhans Cell Tumors

F. Bertucci, R. Bouabdallah, P. Brousset, 2018, The American journal of surgical pathology.

A genome scan for Plasmodium falciparum malaria identifies quantitative trait loci on chromosomes 5q31, 6p21.3, 17p12, and 19p13

F. Fumoux, P. Rihet, S. Garnier, 2014, Malaria Journal.

Targeted NGS, array-CGH, and patient-derived tumor xenografts for precision medicine in advanced breast cancer: a single-center prospective study

F. Bertucci, D. Birnbaum, P. Finetti, 2016, Oncotarget.

Comparative genomic analysis of primary tumors and metastases in breast cancer

F. Bertucci, D. Birnbaum, P. Finetti, 2016, Oncotarget.

Genetic variations in genes involved in heparan sulphate biosynthesis are associated with Plasmodium falciparum parasitaemia: a familial study in Burkina Faso

F. Fumoux, P. Rihet, S. Garnier, 2012, Malaria Journal.

Cyclin A2 maintains colon homeostasis and is a prognostic factor in CRC.

F. Bertucci, P. Finetti, C. Paul, 2020, The Journal of clinical investigation.

Loss of cyclin A2 in murine colonic epithelial cells disrupts colon homeostasis by triggering DNA damage and dysplasia and high cyclin A2 expression is a good-prognosis factor in patients with colorectal cancer

F. Bertucci, P. Finetti, C. Paul, 2019, bioRxiv.

Malaria resistance genes are associated with the levels of IgG subclasses directed against Plasmodium falciparum blood-stage antigens in Burkina Faso

F. Fumoux, P. Rihet, S. Garnier, 2012, Malaria Journal.

Molecular characterization of acute erythroid leukemia (M6-AML) using targeted next-generation sequencing

D. Birnbaum, N. Cervera, N. Vey, 2016, Leukemia.

Common origin of sequential cutaneous CD30+ lymphoproliferations with nodal involvement evidenced by genome‐wide clonal evolution

F. Bertucci, R. Bouabdallah, D. Birnbaum, 2019, Histopathology.

Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate.

F. Bertucci, P. Finetti, O. Cabaud, 2022, Molecular cancer therapeutics.

Revisiting gene mutations and prognosis of ex-M6a-acute erythroid leukemia with regard to the new WHO classification

D. Birnbaum, N. Cervera, N. Vey, 2017, Blood Cancer Journal.